Mad Money with Jim Cramer – Jan 25, 2024 (Thur): Key Points & Links｜要点・関連リンク

This page lists the main topics and stocks discussed on Mad Money with Jim Cramer aired on January 25, 2024, with links to CNBC articles, videos, and English transcripts.

2024年1月25日放送の 「Mad Money with Jim Cramer」 で取り上げられた主な話題・銘柄を、CNBCの記事・動画・英文トランスクリプトへのリンクとともに一覧化しています。

(1) Jim Cramer says it’s time for investors to take some profits, ‘it’s the disciplined thing to do’ (https://www.cnbc.com/2024/01/25/jim-cramer-says-its-time-for-investors-to-take-some-profits.html)

• CNBC’s Jim Cramer on Thursday said the market’s had a substantial run, and investors should take profits while they can.
• “I’m begging you to take something off the table if you haven’t done so already,” he said. “It’s the disciplined thing to do.”

Ticker: CAT [charitable trust owns CAT; sold half position], DD [charitable trust owns DD]

(2) [No Video Clip for non-Club Member] Paccar is a ‘true innovator’, says Jim Cramer (https://www.cnbc.com/video/2024/01/25/paccar-is-a-true-innovator-says-jim-cramer.html)

‘Mad Money’ host Jim Cramer digs into Paccar earnings after the stock hit an all-time high this week.

Ticker: PCAR

(3) [No Video Clip for non-Club Member] IBM proved it’s an AI winner, says Jim Cramer (https://www.cnbc.com/video/2024/01/25/ibm-proved-its-an-ai-winner-says-jim-cramer.html)

‘Mad Money’ host Jim Cramer digs into IBM after the stock popped on quarterly earnings.

Ticker: ServiceNow (NOW), IBM (IBM)

(4) [No Video Clip for non-Club Member] Executive Interview: ResMed CEO Mick Farrell goes one-on-one with Jim Cramer (https://www.cnbc.com/video/2024/01/25/resmed-ceo-mick-farrell-goes-one-on-one-with-jim-cramer.html)

ResMed Chairman and CEO Mick Farrell joins ‘Mad Money’ host Jim Cramer to talk quarterly results, weight loss drugs, growth in its medical device segment and more.

Ticker: RMD

(5) Cramer’s Lightning Round: Buy BlackRock (https://www.cnbc.com/2024/01/25/cramers-lightning-round-buy-blackrock.html)

• SolarEdge: “This one, along with my friend Enphase, they’re just too hard to own.”
• BlackRock: “I think you buy it. Period, end of story. I think that was an amazing quarter. That acquisition Larry Fink was really brilliant and the stock should go much higher.”
• Axsome Therapeutics: “I don’t know it…I have to do more work because so many companies have failed when it comes to central nervous system. More work to do.”
• HanesBrands: “Too early.”

Ticker: SEDG, BLK, AXSM, HBI

(6) After earnings miss, Cramer says Tesla’s out of the Magnificent Seven (https://www.cnbc.com/2024/01/25/after-earnings-miss-cramer-says-teslas-out-of-the-magnificent-seven.html)

• CNBC’s Jim Cramer on Thursday criticized Tesla’s earnings miss and CEO Elon Musk’s leadership, saying the company has lost its spot in the “Magnificent Seven.”
• Unlike its Big Tech peers, Cramer said Tesla is facing serious competition from foreign competitors and is on track for “notably” slowed growth in 2024.

Ticker: TSLA

Other Stocks Discussed (calls with audience)/ この日の放送で取り上げられたその他の銘柄（視聴者からの電話): Columbia Banking System (COLB) [very high yield, call for more scrutiny], UiPath (PATH) [I like your call]

Ref: Links related to this episode /参考: この日の放送に関するその他のサイトへのリンク:

• Podcast at Spotify  (Sound /音声）
• Internet Archive（Video & Texts per minute /1分毎のビデオ＆テキスト）

Disclaimer/ 免責事項

****************************